查看文章

Lipoprotein‐associated phospholipase A₂ (Lp‐PLA2) is a new specific vascular inflammation biomarker that is carried by the lipoproteins in the blood and plays a prominent role in the pathogenesis of atherosclerosis. Increased Lp‐PLA2 levels and impaired Lp‐PLA2 distribution across high‐density lipoprotein (HDL) and non‐HDL lipoproteins have been reported in diabetic patients, which is associated with the increase in cardiovascular disease (CVD) risk. This study is aimed at investigating the effect of alpha lipoic acid (ALA), as an antioxidant with potential cardioprotective properties, on the Lp‐PLA2 mass and its distribution in diabetic patients. In a double‐blind, randomized, placebo‐controlled clinical trial, seventy diabetic patients were randomly allocated to ALA (1200 mg ALA as two 600 mg capsules/day) and placebo (two maltodextrin capsules/day) groups. The serum levels of total Lp‐PLA2 mass, HDL …